文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.

作者信息

Vajdy Michael, Srivastava Indresh, Polo John, Donnelly John, O'Hagan Derek, Singh Manmohan

机构信息

Chiron Vaccines, Emeryville, California 94608, USA.

出版信息

Immunol Cell Biol. 2004 Dec;82(6):617-27. doi: 10.1111/j.1440-1711.2004.01288.x.


DOI:10.1111/j.1440-1711.2004.01288.x
PMID:15550120
Abstract

Almost all vaccinations today are delivered through parenteral routes. Mucosal vaccination offers several benefits over parenteral routes of vaccination, including ease of administration, the possibility of self-administration, elimination of the chance of injection with infected needles, and induction of mucosal as well as systemic immunity. However, mucosal vaccines have to overcome several formidable barriers in the form of significant dilution and dispersion; competition with a myriad of various live replicating bacteria, viruses, inert food and dust particles; enzymatic degradation; and low pH before reaching the target immune cells. It has long been known that vaccination through mucosal membranes requires potent adjuvants to enhance immunogenicity, as well as delivery systems to decrease the rate of dilution and degradation and to target the vaccine to the site of immune function. This review is a summary of current approaches to mucosal vaccination, and it primarily focuses on adjuvants as immunopotentiators and vaccine delivery systems for mucosal vaccines based on protein, DNA or RNA. In this context, we define adjuvants as protein or oligonucleotides with immunopotentiating properties co-administered with pathogen-derived antigens, and vaccine delivery systems as chemical formulations that are more inert and have less immunomodulatory effects than adjuvants, and that protect and deliver the vaccine through the site of administration. Although vaccines can be quite diverse in their composition, including inactivated virus, virus-like particles and inactivated bacteria (which are inert), protein-like vaccines, and non-replicating viral vectors such as poxvirus and adenovirus (which can serve as DNA delivery systems), this review will focus primarily on recombinant protein antigens, plasmid DNA, and alphavirus-based replicon RNA vaccines and delivery systems. This review is not an exhaustive list of all available protein, DNA and RNA vaccines, with related adjuvants and delivery systems, but rather is an attempt to highlight many of the currently available approaches in immunopotentiation of mucosal vaccines.

摘要

相似文献

[1]
Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.

Immunol Cell Biol. 2004-12

[2]
Mucosal delivery of vaccine antigens and its advantages in pediatrics.

Adv Drug Deliv Rev. 2006-4-20

[3]
Mucosal immunisation: adjuvants and delivery systems.

Curr Drug Deliv. 2004-10

[4]
Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines.

Int J Pharm. 2019-10-24

[5]
Nasal and pulmonary vaccine delivery using particulate carriers.

Expert Opin Drug Deliv. 2015-5-8

[6]
New insights in mucosal vaccine development.

Vaccine. 2011-11-12

[7]
Intranasal formulations: promising strategy to deliver vaccines.

Expert Opin Drug Deliv. 2014-10

[8]
Recent advances in vaccine adjuvants for systemic and mucosal administration.

J Pharm Pharmacol. 1998-1

[9]
Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery.

Curr Top Microbiol Immunol. 2012

[10]
Innate endogenous adjuvants prime to desirable immune responses via mucosal routes.

Protein Cell. 2015-3

引用本文的文献

[1]
An updated review on oral protein-based antigen vaccines efficiency and delivery approaches: a special attention to infectious diseases.

Arch Microbiol. 2023-7-19

[2]
Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.

J Virol. 2019-6-28

[3]
Needle-Free Immunization with Chitosan-Based Systems.

Int J Mol Sci. 2018-11-19

[4]
Properties and applications of nanoparticle/microparticle conveyors with adjuvant characteristics suitable for oral vaccination.

Int J Nanomedicine. 2018-5-21

[5]
Liposomal adjuvant development for leishmaniasis vaccines.

Ther Adv Vaccines. 2017-8

[6]
Comparative Safety and Efficacy Profile of a Novel Oil in Water Vaccine Adjuvant Comprising Vitamins A and E and a Catechin in Protective Anti-Influenza Immunity.

Nutrients. 2017-5-21

[7]
Vitamin A or E and a catechin synergize as vaccine adjuvant to enhance immune responses in mice by induction of early interleukin-15 but not interleukin-1β responses.

Immunology. 2016-8

[8]
An Overview of Challenges Limiting the Design of Protective Mucosal Vaccines for Finfish.

Front Immunol. 2015-10-22

[9]
Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines.

Vaccines (Basel). 2015-3-5

[10]
DNA-Encoded Flagellin Activates Toll-Like Receptor 5 (TLR5), Nod-like Receptor Family CARD Domain-Containing Protein 4 (NRLC4), and Acts as an Epidermal, Systemic, and Mucosal-Adjuvant.

Vaccines (Basel). 2013-9-25

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索